Erratum: Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer (Oncotarget (2017) 8 (8162–8172) DOI: 10.18632/oncotarget.14131);Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer

Oncotarget

Volumn 8, Issue 5, 2017, Pages 8162-8172

  Guan, Bing ^a   Wu, Kaijie ^a,b   Zeng, Jin ^a,b   Xu, Shan ^a,b   Mu, Lijun ^a   Gao, Yang ^a   Wang, Ke ^a,b   Ma, Zhenkun ^a,b   Tian, Juanhua ^a   Shi, Qi ^a   Guo, Peng ^a,b   Wang, Xinyang ^a,b   He, Dalin ^a,b   Du, Yuefeng ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Angiogenesis; MicroRNA 218; Prostate cancer; RICTOR; VEGFA

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MICRORNA; MICRORNA 218; RICTOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE;

EID: 85018862639     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/ONCOTARGET.28206     Document Type: Erratum

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90
2. Siegel R L, Miller K D, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians. 2015; 65:5-29
3. Egan A, Dong Y, Zhang H, Qi Y, Balk S P, Sartor O. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat. Rev. 2014; 40:426-433
4. Lim L P, Lau N C, Garrett-Engele P, Grimson A, Schelter J M, Castle J, Bartel D P, Linsley P S, Johnson J M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433:769-773
5. Ambs S, Prueitt R L, Yi M, Hudson R S, Howe T M, Petrocca F, Wallace T A, Liu C G, Volinia S, Calin G A, Yfantis H G, Stephens R M, Croce C M. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008; 68:6162-6170
6. Hobert O. Gene regulation by transcription factors and microRNAs. Science. 2008; 319:1785-1786
7. Iorio M V, Croce C M. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 2009; 27:5848-5856
8. Kuehbacher A, Urbich C, Dimmeler S. Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol. Sci. 2008; 29:12-15
9. Hong L, Han Y, Zhou Y, Nita A. Angiogenesis-related microRNAs in colon cancer. Expert Opin Biol Ther. 2013; 13:77-84
10. Lee D Y, Deng Z, Wang C H, Yang B B. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A. 2007; 104:20350-20355
11. Zhang X, Tang J, Zhi X, Xie K, Wang W, Li Z, Zhu Y, Yang L, Xu H, Xu Z. miR-874 functions as a tumor suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway in gastric cancer. Oncotarget. 2015; 6:1605-1617. doi: 10.18632/oncotarget.2748
12. Hua Z, Lv Q, Ye W, Wong C K, Cai G, Gu D, Ji Y, Zhao C, Wang J, Yang B B, Zhang Y. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. Plos One. 2006; 1:e116
13. Uesugi A, Kozaki K I, Tsuruta T, Furuta M, Morita K I, Imoto I, Omura K, Inazawa J. The Tumor Suppressive MicroRNA miR-218 Targets the mTOR Component Rictor and Inhibits AKT Phosphorylation in Oral Cancer. Cancer Res. 2011; 71:5765-5778
14. Yamasaki T, Seki N, Yoshino H, Itesako T, Hidaka H, Yamada Y, Tatarano S, Yonezawa T, Kinoshita T, Nakagawa M, Enokida H. MicroRNA-218 Inhibits Cell Migration and Invasion in Renal Cell Carcinoma through Targeting Caveolin-2 Involved in Focal Adhesion Pathway. The Journal of Urology. 2013; 190:1059-1068
15. Tu Y, Gao X, Li G, Fu H, Cui D, Liu H, Jin W, Zhang Y. MicroRNA-218 Inhibits Glioma Invasion, Migration, Proliferation, and Cancer Stem-like Cell Self-Renewal by Targeting the Polycomb Group Gene Bmi1., 2013:6046-6055
16. Jackson B L, Grabowska A, Ratan H L. MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers. Bmc Cancer. 2014; 14:930
17. Medina-Villaamil V, Martinez-Breijo S, Portela-Pereira P, Quindos-Varela M, Santamarina-Cainzos I, Anton-Aparicio L M, Gomez-Veiga F. Circulating MicroRNAs in blood of patients with prostate cancer. Actas Urol. Esp. 2014; 38:633-639
18. Lee R C, Feinbaum R L, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75:843-854
19. Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res. 2004; 32:D109-D111
20. Garzon R, Marcucci G, Croce C M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 2010; 9:775-789
21. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins J F, Bader A G, Fagin R, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011; 17:211-215
22. Zhu X, Er K, Mao C, Yan Q, Xu H, Zhang Y, Zhu J, Cui F, Zhao W, Shi H. miR-203 suppresses tumor growth and angiogenesis by targeting VEGFA in cervical cancer. Cell. Physiol. Biochem. 2013; 32:64-73
23. Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, Li Q, Qiao T, Zhao Q, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. Plos Genet. 2010; 6:e1000879
24. Alajez N M, Lenarduzzi M, Ito E, Hui A B, Shi W, Bruce J, Yue S, Huang S H, Xu W, Waldron J, O'Sullivan B, Liu F F. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 2011; 71:2381-2391
25. Kogo R, How C, Chaudary N, Bruce J, Shi W, Hill R P, Zahedi P, Yip K W, Liu F F. The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer. Oncotarget. 2015; 6:1090-1100 doi: 10.18632/oncotarget.2836
26. Leite K R, Sousa-Canavez J M, Reis S T, Tomiyama A H, Camara-Lopes L H, Sanudo A, Antunes A A, Srougi M. Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol. 2011; 29:265-269
27. Nishikawa R, Goto Y, Sakamoto S, Chiyomaru T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya Y, Ichikawa T, Seki N. Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer. Cancer Sci. 2014; 105:802-811
28. Han G, Fan M, Zhang X. microRNA-218 inhibits prostate cancer cell growth and promotes apoptosis by repressing TPD52 expression. Biochem. Bioph. Res. Co. 2015; 456:804-809
29. Azoitei N, Pusapati G V, Kleger A, Moller P, Kufer R, Genze F, Wagner M, van Lint J, Carmeliet P, Adler G, Seufferlein T. Protein kinase D2 is a crucial regulator of tumour cellendothelial cell communication in gastrointestinal tumours. Gut. 2010; 59:1316-1330
30. Kieran M W, Kalluri R, Cho Y J. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med. 2012; 2:a6593
31. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011; 146:873-887
32. Carmeliet P, Jain R K. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473:298-307
33. Fan R, Zhong J, Zheng S, Wang Z, Xu Y, Li S, Zhou J, Yuan F. microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway. Clin. Exp. Med. 2015; 15:137-144
34. Zhang X, Shi H, Tang H, Fang Z, Wang J, Cui S. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway. Int. J. Mol. Med. 2015; 35:1301-1308
35. Gao Y, Wu K, Chen Y, Zhou J, Du C, Shi Q, Xu S, Jia J, Tang X, Li F, Hui K, He D, Guo P. Beyond proliferation: KLF5 promotes angiogenesis of bladder cancer through directly regulating VEGFA transcription. Oncotarget. 2015; 6:43791-43805. doi: 10.18632/oncotarget.6101